ES2671639T3 - Métodos para controlar la presión arterial y reducir la disnea en la insuficiencia cardiaca - Google Patents

Métodos para controlar la presión arterial y reducir la disnea en la insuficiencia cardiaca Download PDF

Info

Publication number
ES2671639T3
ES2671639T3 ES13848937.2T ES13848937T ES2671639T3 ES 2671639 T3 ES2671639 T3 ES 2671639T3 ES 13848937 T ES13848937 T ES 13848937T ES 2671639 T3 ES2671639 T3 ES 2671639T3
Authority
ES
Spain
Prior art keywords
clevidipine
blood pressure
patient
pharmaceutical composition
patients
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES13848937.2T
Other languages
English (en)
Spanish (es)
Inventor
Edward C. SPINDLER Jr.
Loretta M. ITRI
Gregory Charles Williams
Ming-yi HU
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chiesi Farmaceutici SpA
Original Assignee
Chiesi Farmaceutici SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chiesi Farmaceutici SpA filed Critical Chiesi Farmaceutici SpA
Application granted granted Critical
Publication of ES2671639T3 publication Critical patent/ES2671639T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Vascular Medicine (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Dermatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
ES13848937.2T 2012-10-26 2013-10-26 Métodos para controlar la presión arterial y reducir la disnea en la insuficiencia cardiaca Active ES2671639T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261719127P 2012-10-26 2012-10-26
US201261719127P 2012-10-26
PCT/US2013/066990 WO2014066870A1 (en) 2012-10-26 2013-10-26 Methods for controlling blood pressure and reducing dyspnea in heart failure

Publications (1)

Publication Number Publication Date
ES2671639T3 true ES2671639T3 (es) 2018-06-07

Family

ID=50545374

Family Applications (1)

Application Number Title Priority Date Filing Date
ES13848937.2T Active ES2671639T3 (es) 2012-10-26 2013-10-26 Métodos para controlar la presión arterial y reducir la disnea en la insuficiencia cardiaca

Country Status (18)

Country Link
US (1) US10881645B2 (enExample)
EP (1) EP2925128B1 (enExample)
JP (2) JP6329957B2 (enExample)
KR (1) KR102299073B1 (enExample)
CN (2) CN104968199A (enExample)
AU (1) AU2013334081B2 (enExample)
BR (1) BR112015009291B1 (enExample)
CA (1) CA2889584C (enExample)
EA (1) EA030354B1 (enExample)
ES (1) ES2671639T3 (enExample)
IL (1) IL238462A0 (enExample)
MX (1) MX359768B (enExample)
NZ (1) NZ708511A (enExample)
PL (1) PL2925128T3 (enExample)
TR (1) TR201807636T4 (enExample)
UA (1) UA117571C2 (enExample)
WO (1) WO2014066870A1 (enExample)
ZA (1) ZA201503741B (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102380701B1 (ko) * 2014-05-19 2022-03-31 치에시 파마슈티시 에스.피.아. 클레비디핀 나노입자 및 그의 제약적 조성물
EP3934654A1 (en) * 2019-03-05 2022-01-12 Windtree Therapeutics, Inc. Istaroxime-containing intravenous formulation for the treatment of acute heart failure (ahf)
CN114966056B (zh) * 2022-06-08 2024-07-02 四川大学华西医院 筛查急性主动脉夹层的试剂盒和系统

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9303657D0 (sv) 1993-11-05 1993-11-05 Astra Ab Short-acting dihydropyridines
SE9303744D0 (sv) 1993-11-12 1993-11-12 Astra Ab Pharmaceutical emulsion
SE9804002D0 (sv) 1998-11-23 1998-11-23 Astra Ab New manufacturing process
CA2724540C (en) 2008-05-16 2014-07-08 Corthera, Inc. Treating dyspnea associated with acute heart failure with relaxin
KR101772602B1 (ko) 2008-08-01 2017-08-29 치에시 파마슈티시 에스.피.아. 약제학적 조성물 및 그의 저 불순물 농축물을 제조하는 방법
WO2010014234A1 (en) 2008-08-01 2010-02-04 The Medicines Company Pharmaceutical compositions and methods for stabilizing the same
BR112012011298B1 (pt) 2009-11-11 2021-12-14 Chiesi Farmaceutici S.P.A. Uso de cangrelor e/ou bivalirudina na preparação de medicamentos e combinação de medicamentos
TW201215392A (en) 2010-06-16 2012-04-16 Gilead Sciences Inc Use of ranolazine for treating pulmonary hypertension
JP6040437B2 (ja) * 2010-10-12 2016-12-07 チエシイ ファルマセウティシ ソシエタ ペル アチオニＣｈｉｅｓｉ Ｆａｒｍａｃｅｕｔｉｃｉ Ｓ．Ｐ．Ａ． 抗菌剤を含むクレビジピン乳化製剤
BR112013025368A8 (pt) * 2011-04-01 2018-06-12 The Medicines Co Medicamento, método para preparar um medicamento útil para reduzir danos por derrame em um sujeito com derrame, método para preparar um medicamento útil para reduzir a pressão sanguínea e reduzir danos por derrame em um sujeito com derrame

Also Published As

Publication number Publication date
MX2015005341A (es) 2016-05-24
EP2925128B1 (en) 2018-04-11
EP2925128A1 (en) 2015-10-07
CN104968199A (zh) 2015-10-07
CN110840890A (zh) 2020-02-28
BR112015009291A2 (pt) 2017-07-04
ZA201503741B (en) 2022-09-28
TR201807636T4 (tr) 2018-06-21
AU2013334081A1 (en) 2015-06-11
NZ708511A (en) 2018-11-30
US20140121247A1 (en) 2014-05-01
KR20150104084A (ko) 2015-09-14
CA2889584C (en) 2018-08-14
CA2889584A1 (en) 2014-05-01
JP2015535258A (ja) 2015-12-10
EP2925128A4 (en) 2016-06-08
US10881645B2 (en) 2021-01-05
AU2013334081B2 (en) 2017-05-18
KR102299073B1 (ko) 2021-09-09
EA201590825A1 (ru) 2015-09-30
BR112015009291B1 (pt) 2021-03-16
WO2014066870A1 (en) 2014-05-01
JP2018065875A (ja) 2018-04-26
EA030354B1 (ru) 2018-07-31
UA117571C2 (uk) 2018-08-27
IL238462A0 (en) 2015-06-30
MX359768B (es) 2018-10-10
JP6329957B2 (ja) 2018-05-23
PL2925128T3 (pl) 2018-10-31

Similar Documents

Publication Publication Date Title
ES2584509T3 (es) Composiciones para el tratamiento del ictus o accidente cerebrovascular con un agonista del receptor de endotelina B
US10493124B2 (en) Angiotensin II alone or in combination for the treatment of hypotension
ES2914060T3 (es) Combinación de dofetilida y mexiletina para la prevención y el tratamiento de la fibrilación auricular
US10987332B2 (en) Sprayable aqueous composition comprising glyceryl trinitrate
ES2671639T3 (es) Métodos para controlar la presión arterial y reducir la disnea en la insuficiencia cardiaca
ES2569123T3 (es) Infusión lenta de sulcardina y sus sales
ES2249707T3 (es) Tratameinto de combinacion para infarto de miocardio agudo.
HK40020897A (en) Methods for controlling blood pressure and reducing dyspnea in heart failure
ES2380913T3 (es) Uso de L-carnitina para el tratamiento de enfermerdades cardiovasculares
EP3482757A1 (en) Use of stabilized granules containing glyceryl trinitrate for arteriogenesis
HK1093869B (en) Pharmaceutical formulations, methods and dosing regimens for the treatment and prevention of acute coronary syndromes